COMPOSITION AND METHODS OF INHIBITING GASTROINTESTINAL PATHOGEN INFECTION

• US 20130012472A1
• Filed: 07/05/2012
• Published: 01/10/2013
• Est. Priority Date: 07/05/2011
• Status: Abandoned Application

• Current Assignee: Trustees of Boston College (Boston College)
• Original Assignee: Boston College
• Inventors: NEWBURG, David S., HE, Yingying
• Application Number:
  US13/542,302
• Publication Number:
  US 20130012472A1
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A61K 31/726 Glycosaminoglycans, i.e. mucopolysaccharides chondroitin sulfate, dermatan sulfate A61K31/737
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions comprising a milk-derived oligosaccharide such as trifucosyl(1,2-1,2-1,3)-lacto-N-octoase (TFiLNO) and uses thereof for inhibiting invasion of gastrointestinal pathogen into intestinal epithelial cells or for treating an infectious disease (e.g., a disease caused by a gastrointestinal pathogen such as an ETEC) or an inflammatory diseases such as inflammatory bowel disease.

Claims

1. A method for inhibiting invasion of intestinal epithelial cells by a gastrointestinal pathogen, the method comprising administering to a subject in need thereof a synthetic composition that comprises a milk-derived oligosaccharide, wherein the milk-derived oligosaccharide is in an amount effective to inhibit the invasion.

2. The method of claim 1, wherein the milk-derived oligosaccharide is trifucosyl (1,2-1, 2-1,3)-lacto-N-octoase (TFiLNO) or a fragment thereof.

3. The method of claim 1, wherein the composition comprises mammalian milk oligosaccharides (MMOS).

4. The method of claim 3, wherein the MMOS is human milk oligosaccharides (HMOS).

5. The method of claim 1, wherein the gastrointestinal pathogen is an Enterotoxigenic Escherichia coli (ETEC).

6. The method of claim 1, wherein the subject is a human subject who is infected, suspected of being infected, or at risk for infection by the gastrointestinal pathogen.

7. The method of claim 6, wherein the human subject is a child under 5.

8. The method of claim 7, wherein the human subject is an infant.

9. The method of claim 6, wherein the human subject has or is suspected of having an inflammatory bowel disease.

10. The method of claim 1, wherein the synthetic composition is administered orally.

11. The method of claim 1, wherein the milk-derived oligosaccharide is in an amount effective to reduce inflammation induced by the invasion.

12. The method of claim 1, wherein the synthetic composition is a pharmaceutical composition, which further comprises a pharmaceutically acceptable carrier.

13. The method of claim 1, wherein the synthetic composition is a nutritional composition.

14. The method of claim 1, wherein the synthetic composition is an infant formula.

15. A method for treating an infectious or inflammatory disease, comprising administering to a subject in need thereof an effective amount of trifucosyl (1,2-1, 2-1,3)-lacto-N-octoase (TFiLNO).

16. The method of claim 15, wherein the infectious disease is caused by a gastrointestinal pathogen.

17. The method of claim 16, wherein the gastrointestinal pathogen is an ETEC.

18. The method of claim 15, wherein the subject is a human subject who is infected, suspected of being infected, or at risk for the infectious or inflammatory disease.

19. The method of claim 15, wherein the inflammatory disease is IBD.

20. A synthetic composition, comprising trifucosyl (1,2-1, 2-1,3)-lacto-N-octoase (TFiLNO) or a fragment thereof, wherein the composition is substantially free of MMOS.

21. The synthetic composition of claim 20, wherein the composition is a pharmaceutical composition, which further comprises a pharmaceutically acceptable carrier.

22. The synthetic composition of claim 20, wherein the composition is a nutritional composition.

23. The synthetic composition of claim 20, wherein the composition is an infant formula.